A phase II trial of gemcitabine (G), carboplatin (C), and sorafenib (S) in patients (pts) with transitional cell carcinoma (TCC): Preliminary safety and outcome. Background: Frail and elderly patients ...
Surgery for advanced bladder cancer includes transurethral resection of the bladder tumor (TURBT) to remove tumors and cystectomy to remove all or part of the bladder, with the choice depending on the ...
A phase II clinical trial of intravesical YH01 for BCG-unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC). RAD-SG: Adaptive radiation therapy with concurrent sacituzumab govitecan for ...
UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers Mar 05, 2026, 1:53 AM ET UroGen Pharma Ltd. (URGN) Stock Out of Ignorance 7.69K Followers ...
Treatments for bladder cancer include surgery, chemotherapy, and radiation therapy. Newer treatment options include immunotherapy and targeted therapy. Doctors may administer medications directly into ...
A TURBT allows examination beyond the bladder. Complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy in patients scheduled to undergo radical cystectomy for ...
In a trial of low-grade Ta bladder cancer, photocoagulation was noninferior to standard TURBT in maintaining recurrence-free survival. Office-based laser photocoagulation provides 12-month ...
The BladderPath study showed mpMRI reduced TTCT by 45 days for MIBC patients, enhancing treatment efficiency without harming non-MIBC patients. Conducted in 17 UK hospitals, the study involved 143 ...
Bladder cancer is the seventh most common cancer in men, with nearly 400,000 cases diagnosed per year. However, despite the use of transurethral resection of the bladder tumor (TURBT), a large number ...
Neoadjuvant mitomycin C showed a favorable safety profile with mild to moderate side effects, including hematuria, dysuria, and itchy scalp. The trial did not show significant improvement in 12-month ...
Investors will have to wait for durability of response (DoR) data from Urogen Pharma Ltd.’s phase III Envision study with UGN-102 (mitomycin intravesical solution) in low-grade, intermediate-risk, non ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results